서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Subject

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 41 to 80 of 103

Issue DateTitle / Author(s) / CitationFileAltmetrics
2016-04
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
DOI
2016-05
Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer
DOI
2016-05
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
DOI
2016-06
The purpose and appropriateness of carbapenem use in a single university hospital, 2009-2013
DOI
2016-07
Serum Neuron-Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations
DOI
2016-08
Overexpression of HIF1α and CAXI predicts poor outcome in early-stage triple negative breast cancer
DOI
2016-12
Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer
DOI
2016-12
Clonal evolutionary analysis during HER2 blockade in HER2-positive inflammatory breast cancer: A phase II open-label clinical trial of afatinib plus /- vinorelbine
DOI
2017
EXPLORING THE EPIDEMIOLOGICAL IMPACT OF UNIVERSAL ACCESS TO RAPID TUBERCULOSIS DIAGNOSIS USING AGENT-BASED SIMULATION
2017-01
Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment
DOI
2017-02
Institutional factors affecting participation in national faculty development programs: a nation-wide investigation of medical schools

Kim, Do-Hwan; Hwang, Jinyoung; Lee, Seunghee; Shin, Jwa-Seop

BMC Medical Education, Vol.17, p. 48

DOI
2017-02
Characteristics of cefazolin inoculum effect-positive methicillin-susceptible staphylococcus aureus infection in a multicentre bacteraemia cohort
DOI
2017-06
Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma
view fileDOI
2017-07
Effects of preoperative aspirin on perioperative platelet activation and dysfunction in patients undergoing off-pump coronary artery bypass graft surgery: A prospective randomized study
DOI
2017-07
Effects of preoperative aspirin on perioperative platelet activation and dysfunction in patients undergoing off-pump coronary artery bypass graft surgery: A prospective randomized study
DOI
2017-07
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
DOI
2017-08
Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement
DOI
2017-08
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
DOI
2017-08
Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer
DOI
2017-08
Continuous O-2-Evolving MnFe2O4 Nanoparticle-Anchored Mesoporous Silica Nanoparticles for Efficient Photodynamic Therapy in Hypoxic Cancer

Kim, Jonghoon; Cho, Hye Rim; Jeon, Hyejin; Kim, Dokyoon; Song, Changyeong; Lee, Nohyun; Choi, Seung Hong; Hyeon, Taeghwan

Journal of the American Chemical Society, Vol.139 No.32, pp.10992-10995

DOI
2017-12
The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies
DOI
2017-12
Anti-tumor effects of NVP-BKM120 alone or in combination with MEK162 in biliary tract cancer
DOI
2018-04
Profiling of protein-protein interactions via single-molecule techniques predicts the dependence of cancers on growth-factor receptors
DOI
2018-05
Phase II study of crizotinib in east asian patients with ROS1-positive advanced non–small-cell lung cancer
DOI
2018-06
Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma

Yang, Jeong Mi; Jang, Ji-Young; Jeon, Yoon Kyung; Paik, Jin Ho

Journal of Translational Medicine, Vol.16 No.1, p. 162

DOI
2018-07
Change in topoisomerase 1–positive circulating tumor cells affects overall survival in patients with advanced breast cancer after treatment with etirinotecan pegol
DOI
2018-11
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2
DOI
2018-11
Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer
DOI
2018-12
A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial
DOI
2019-01
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
DOI
2019-05
Unstable genome and transcriptome dynamics during tumor metastasis contribute to therapeutic heterogeneity in colorectal cancers
DOI
2019-06
Point of care Xpert MTB/RIF versus smear microscopy for tuberculosis diagnosis in southern African primary care clinics: a multicentre economic evaluation
DOI
2019-08
Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer
DOI
2019-09
GC1118, a novel anti-EGFR antibody, has potent KRAS mutation-independent antitumor activity compared with cetuximab in gastric cancer
DOI
2019-09
Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients
DOI
2019-09
Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer

Ock, Chan-Young; Yoo, Shin-Hye; Keam, Bhumsuk; Kim, Miso; Kim, Tae Min; Jeon, Yoon Kyung; Kim, Dong Wan; Chung, Doo Hyun; Heo, Dae Seog

The Korean Journal of Internal Medicine, Vol.34 No.5, pp.1116-1124

view fileDOI
2019-09
Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations

Lee, Yusoo; Kim, Tae Min; Kim, Dong-Wan; Kim, Soyeon; Kim, Miso; Keam, Bhumsuk; Ku, Ja-Lok; Heo, Dae Seog

Journal of Thoracic Oncology, Vol.14 No.9, pp.1556-1566

DOI
2019-12
Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2+metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
DOI
2020
Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma
view fileDOI
2020-01
A Prospective Cohort Study of Durations of Staphylococcus aureus Bacteremia According to Different Phenotypes and a New Concept of Persistent Bacteremia
DOI
1 2 3